What is the USPSTF stance on PSA-based screening for prostate cancer?

• A. Individualized decision-making for men 55-69; not routinely recommended for all; generally not recommended for men 70+
• B. Routinely recommended for all men aged 50-75
• C. Not recommended for any age
• D. Recommended annually for men 40-60

Answer: (A)

The main idea is that PSA-based screening is not a blanket recommendation. The USPSTF favors a shared decision-making approach for most men in a specific age window, and it discourages routine screening in older men due to harms outweighing benefits.

For men around 55 to 69 years old, there can be a modest potential benefit in reducing prostate cancer deaths, but this is balanced by substantial risks from overdiagnosis and overtreatment, biopsies, and treatment side effects like erectile dysfunction and urinary incontinence. Because the net benefit is small and highly individual, the recommendation is to have a careful discussion with a clinician and make a decision based on personal values, risk factors, and preferences rather than screening everyone in that age group.

For men aged 70 and older, the balance tips toward harms, so routine PSA screening is not recommended.

Why the other statements don’t fit: screening everyone in the 50–75 or any fixed age range ignores the nuanced balance of benefits and harms, and routine annual screening starting at age 40 isn’t supported by the evidence. The guidelines don’t endorse universal screening or a one-size-fits-all schedule; they emphasize individualized decisions within a defined age range and avoiding routine screening in older adults.